Life Sciences

Genedrive Plc

Based on Epistem's proprietary technology, the Genedrive® molecular diagnostic system has been developed as an affordable next generation genotyping and sequence analysis device, providing rapid detection and diagnosis in approximately 45-75 minutes depending on the test. Genedrive® has been designed as a simple-to-use handheld device with high multiplexing capability.
The first test developed on the Genedrive® is the HCV-ID test, which allows small/medium laboratories to test for hepatitis infection, thus speeding up diagnosis and treatment, and improving patients’ prognosis. Genedrive® analyses nucleic acids from fresh or stored samples or biospecimens.

Market: AIM

Ticker: GDR

Lead analyst: Dr Martin Hall